Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)

NCT03820908 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT03820908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03820908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)
Lead sponsor
Sheba Medical Center
Phase
Phase 2
Overall status
Completed
Start date
July 18, 2019
Completion date
July 22, 2020
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, allogeneic stem cell transplantation